Opioids Compared With Placebo or Other Treatments for Chronic Low Back Pain An Update of the Cochrane Review

被引:175
作者
Chaparro, Luis Enrique [1 ]
Furlan, Andrea D. [2 ]
Deshpande, Amol [3 ]
Mailis-Gagnon, Angela
Atlas, Steven [4 ]
Turk, Dennis C. [5 ]
机构
[1] Hosp Pablo Tobon Uribe, Dept Anesthesiol, Medellin, Colombia
[2] Inst Work & Hlth, Toronto, ON, Canada
[3] Univ Hlth Network, Toronto Western Hosp, Comprehens Pain Program, Toronto, ON, Canada
[4] Massachusetts Gen Hosp, Med Practices Evaluat Ctr, Boston, MA 02114 USA
[5] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA
关键词
analgesics; opioid/adverse effects; opioid/therapeutic use; buprenorphine/therapeutic use; Cochrane Review; hydromorphone/therapeutic use; low back pain/drug therapy; metaanalysis; morphine/therapeutic use; oxycodone/therapeutic use; oxymorphone/therapeutic use; sciatica/drug therapy; systematic review; tramadol/therapeutic use; TRAMADOL/ACETAMINOPHEN COMBINATION TABLETS; BUPRENORPHINE TRANSDERMAL SYSTEM; OXYMORPHONE EXTENDED-RELEASE; CHRONIC NONCANCER PAIN; DOUBLE-BLIND; CONTROLLED-TRIAL; EFFICACY; SAFETY; MODERATE; THERAPY;
D O I
10.1097/BRS.0000000000000249
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Study Design. Systematic review and meta-analysis. Objective. To assess the efficacy of opioids in adults with chronic low back pain (CLBP). Summary of Background Data. Opioids for CLBP has increased dramatically. However, the benefits and risks remain unclear. Methods. We updated a 2007 Cochrane Review through October 2012 of randomized controlled trials from multiple databases. Use of noninjectable opioids in CLBP for at least 4 weeks was compared with placebo or other treatments; comparisons with different opioids were excluded. Outcomes included pain and function using standardized mean difference (SMD) or risk ratios with 95% confidence intervals (CIs), and absolute risk difference with 95% CI for adverse effects. Study quality was evaluated using Grading of Recommendations Assessment, Development, and Evaluation criteria. Results. Fifteen trials (5540 participants), including twelve new, met the criteria. Tramadol was better than placebo for pain (SMD, -0.55; 95% CI, -0.66 to -0.44) and function (SMD, -0.18; 95% CI, -0.29 to -0.07). Compared with placebo, transdermal buprenorphine decreased pain (SMD, -2.47; 95% CI, -2.69 to -2.25), but not function (SMD, -0.14; 95% CI, -0.53 to 0.25). Strong opioids (morphine, hydromorphone, oxycodone, oxymorphone, and tapentadol), were better than placebo for pain (SMD, -0.43; 95% CI, -0.52 to -0.33) and function (SMD, -0.26; 95% CI, -0.37 to -0.15). One trial demonstrated little difference with tramadol compared with celecoxib for pain relief. Two trials (272 participants) found no difference between opioids and antidepressants for pain or function. Reviewed trials had low to moderate quality, high drop-out rates, short duration, and limited interpretability of functional improvement. No serious adverse effects, risks (addiction or overdose), or complications (sleep apnea, opioid-induced hyperalgesia, hypogonadism) were reported. Conclusion. There is evidence of short-term efficacy (moderate for pain and small for function) of opioids to treat CLBP compared with placebo. The effectiveness and safety of long-term opioid therapy for treatment of CLBP remains unproven.
引用
收藏
页码:556 / 563
页数:8
相关论文
共 38 条
[1]
Epidemiological features of chronic low-back pain [J].
Andersson, GBJ .
LANCET, 1999, 354 (9178) :581-585
[2]
[Anonymous], SPINE PHILA PA 1976
[3]
[Anonymous], SPINE PHILA PA 1976
[4]
Opioid therapy for chronic pain [J].
Ballantyne, JC ;
Mao, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (20) :1943-1953
[5]
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study [J].
Buynak, Robert ;
Shapiro, Douglas Y. ;
Okamoto, Akiko ;
Van Hove, Ilse ;
Rauschkolb, Christine ;
Steup, Achim ;
Lange, Bernd ;
Lange, Claudia ;
Etropolski, Mila .
EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (11) :1787-1804
[6]
Analgesic tolerance without demonstrable opioid-induced hyperalgesia: a double-blinded, randomized, placebo-controlled trial of sustained-release morphine for treatment of chronic nonradicular low-back pain [J].
Chu, Larry F. ;
D'Arcy, Nicole ;
Brady, Caitlin ;
Zamora, Abigail Kathleen ;
Young, Chelsea Anne ;
Kim, Julie Eunwoo ;
Clemenson, Anna Marie ;
Angst, Martin S. ;
Clark, J. David .
PAIN, 2012, 153 (08) :1583-1592
[7]
Opioids for chronic low-back pain [J].
Deshpande, A. ;
Furlan, A. ;
Mailis-Gagnon, A. ;
Atlas, S. ;
Turk, D. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (03)
[8]
Back pain prevalence and visit rates - Estimates from US national surveys, 2002 [J].
Deyo, Richard A. ;
Mirza, Sohail K. ;
Martin, Brook I. .
SPINE, 2006, 31 (23) :2724-2727
[9]
A comparison between enriched and nonenriched enrollment randomized withdrawal trials of opioids for chronic noncancer pain [J].
Furlan, Andrea D. ;
Chaparro, Luis E. ;
Irvin, Emma ;
Mailis-Gagnon, Angela .
PAIN RESEARCH & MANAGEMENT, 2011, 16 (05) :337-351
[10]
Opioids for chronic noncancer pain: a new Canadian practice guideline [J].
Furlan, Andrea D. ;
Reardon, Rhoda ;
Weppler, Clarence .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2010, 182 (09) :923-930